Aminex Therapeutics

Kenmore, WA · Founded 2009 · Privately Held (backing)

Operator of a drug development company intended to focus on advancing novel immunotherapy for cancer treatment and cure. Aminex Therapeutics is based in Kenmore, WA and was founded in 2009. It was valued at $105 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $47.6 million across 6 recorded rounds; the latest was a $15.1 million early-stage round in Oct 2022.

PMV mark · valuation
$105.1M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$47.6M
Last round
Early Stage VC
Oct 2022
What is Aminex Therapeutics worth?
$105.1MPrivateMarketView mark · Oct 2026

Valued at $105.1M at its later-stage round, Dec 2025. Nothing has traded since.

Free account
More of Aminex Therapeutics with a free account
  • ·Watch Aminex Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Aminex Therapeutics funding history

6 rounds
DateRoundRaisedPost-money
Oct 2022Early Stage VC$15.1M▮
Aug 2021Early Stage VC$6.3M▮
Jul 2020Debt$2.9M▮
May 2018Early Stage VC$8.3M▮
Oct 2014Seed Round$410K▮
Jun 2014Seed Round$1.6M▮
Unlock post-money valuations

Membership and data by Private Market View

Aminex Therapeutics valuation

Aminex Therapeutics was valued at $105 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Aminex Therapeutics raised?

Aminex Therapeutics has raised $47.6 million across 6 recorded rounds since 2014. The largest was an $8.3 million early-stage round in May 2018; the most recent was a $15.1 million early-stage round in Oct 2022.

Aminex Therapeutics has filed 6 Form Ds with the SEC since 2014, most recently in Dec 2025 ($15.1 million sold to 162 investors).

How Aminex Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Aminex Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Aminex Therapeutics

What is Aminex Therapeutics worth?
Aminex Therapeutics is valued at $105.1M as of Oct 2026. Valued at $105.1M at its later-stage round, Dec 2025. Nothing has traded since.
How much has Aminex Therapeutics raised?
Aminex Therapeutics has raised $47.6M in total funding across 6 recorded rounds.
When did Aminex Therapeutics last raise?
Aminex Therapeutics last raised in Oct 2022 (Early Stage VC), raising $15.1M.